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Abstract: A preclinical model could aid in understanding retinoblastoma vitreous seeds behavior,
drug penetration, and response to chemotherapy to optimize patient treatment. Our aim was to
develop a tridimensional in vitro model of retinoblastoma vitreous seeds to assess chemotherapy
penetration by means of live-cell imaging. Cell cultures from patients with retinoblastoma who
underwent upfront enucleation were established and thoroughly characterized for authentication of
human tumor origin. The correlation of the in vitro tridimensional structures resembling human
spheres and dusts vitreous seeds was established. Confocal microscopy was used to quantify
real-time fluorescence of topotecan as a measure of its penetration into different sizes of spheres.
Cell viability was determined after chemotherapy penetration. The in vitro spheres and dusts
models were able to recapitulate the morphology, phenotype, and genotype of patient vitreous
seeds. The larger the size of the spheres, the longer the time required for the drug to fully penetrate
into the core (p < 0.05). Importantly, topotecan penetration correlated with its cytotoxic activity.
Therefore, the studied tridimensional cell model recapitulated several characteristics of vitreous seeds
observed in patients with retinoblastoma and were successfully used to assess live-cell imaging of
chemotherapy penetration for drug distribution studies.
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1. Introduction
Retinoblastoma is the most common intraocular tumor of childhood affecting 1 in 15,000 to 1 in
18,000 live births [1–3]. Retinoblastoma is highly curable if diagnosed in the early stages. For decades,
surgical removal of the affected eye (or both eyes in cases of bilateral retinoblastoma) has been the first
choice. Later on, the introduction of chemotherapy provided the basis for eye preservation. Over the
last decade, retinoblastoma treatment has radically changed from using systemic chemotherapy
infusion, with low bioavailability in the ocular tissues but high in plasma, and thus severe systemic
adverse events, to highly-selective novel techniques of drug delivery, including direct ophthalmic
artery chemotherapy and intravitreous injection [3–5]. Though a striking increase in ocular survival
has been attained, eyes with tumors that grow from the retina to the vitreous humor, namely vitreous
seeds, are more difficult to cure and may relapse. Therefore, vitreous seeds remain a challenge in the
management of intraocular retinoblastoma and removal of the affected eye may be the only treatment
option [5,6]. Recently, Munier et al. classified vitreous seeds into “dust”, “spheres”, and “clouds”
based on their heterogeneous appearance at fundoscopy [6]. Dusts are composed of loose tumor cells in
the vitreous, clouds are dense tumor fragments formed by translocation of the primary tumor content to
the vitreous, and spheres are translucent solid tumors formed by further clonal growth of the dust or
the cloud, or by sprouting of the primary retinal tumor [7]. Each class of seeds required a different
cumulative dose and number of intravitreal injections of melphalan to achieve complete response to
treatment [7–10]. Later on, each class of seeds is also correlated with histopathological features [11].
In general, clouds need the greatest number of melphalan injections (and cumulative doses) followed
by spheres, and finally dusts [8–10]. Dusts might be more sensitive to treatment because they are more
accessible to drugs, as they are composed of clusters of loose cells, while spheres or clouds grow as
tight clusters with different layers of viable cells and may hamper homogeneous distribution of the
drug after intravitreal injections [8,9]. Thus, assessment of the capacity of chemotherapy to penetrate
into the tumor seeds, and thereby to become available to exert its cytotoxic effect would certainly
add to the knowledge on and improvement of chemotherapy use and patient management.
Among the antineoplastic agents used for retinoblastoma, topotecan has been widely used
based on its effect in preclinical models and clinical studies [12]. To quantify topotecan penetration
into living tumorspheres, confocal microscopy could be used as topotecan in a fluorescent drug [13,14].
This powerful technique allows for the visualization of structures, including living cells and even thick
living specimens, after noninvasive serial optical sectioning [15].
Over the last years, the development of three-dimensional (3D) in vitro tumor models allowed
the establishment of structural complex cell-cell interactions in systems that resemble in vivo
tumors [16,17]. Still, further developments using 3D tumor culture technology are needed for
translational studies in retinoblastoma. Thus, we explored a scaffold-free culture method allowing
self-aggregation of tumor cells into a 3D structure to closely resemble vitreous seeds. In serum-free,
growth factor-supplemented culture conditions, retinoblastoma cells grow in suspension and form
tumorspheres that may recapitulate vitreous seeds of the spheres class observed in vivo, providing a
suitable in vitro tumor model to study drug penetration [18,19]. In contrast, commercial retinoblastoma
cell lines grow as loose aggregates, resembling vitreous seeds classified as dust.
Thus, the aim of our study was to establish and characterize tumorpsheres derived from patients
with intraocular retinoblastoma and use them to assess if differences in tridimensional conformations
and sphere size affect topotecan penetration using confocal microscopy. The developed tridimensional
cell model resembles several characteristics of vitreous seeds in pediatric patients with intraocular
tumors. This model was useful to assess live-cell imaging of chemotherapy penetration for drug
distribution studies and cytotoxicity assessment.
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2. Results
2.1. Patient-Derived Tumorspheres Resemble the Original Tumor
Early-passage cell cultures derived from intraocular tumors of two patients who underwent
upfront enucleation without receiving previous treatment were obtained and named after the codes
HPG-RBT-12L and HPG-RBT-26. They were considered established after three passages, each one
performed during the log-phase growth.
Analysis of DNA showed that in both primary cells the RB1 gene mutations were
germline and single base substitutions. RB1 mutation in HPG-RBT-12L cells, as well as in the
parental tumor was identified as a point mutation in exon 15 (NM_000321.2(RB1):c.1421G>T)
associated with altered splicing, while for the HPG-RBT-26 cells and tumor in exon 23
(NM_000321.2(RB1):c.2359C>T(p.Arg787*)), it was associated with a premature stop codon. Moreover,
the short tandem profile (STR) for the DNA from the cell lines was identical to that obtained for the
tumor DNA (Tumor samples: HPG-RBT-12T and HPG-RBT-26T), confirming the origin of the cell
cultures (Table 1). There was no significant overlap between both primary cell lines and no cell line
corresponded to the DNA profile of the present retinoblastoma cell lines in the STR database of the
American Type Culture Collection.
Table 1. Short Tandem Repeat analysis of the cell lines and matched tumors.
Marker
Cell Line Tumor Cell Line Tumor
HPG-RBT-12L HPG-RBT-12T HPG-RBT-26 HPG-RBT-26T
Amelogenin X X X X
D3S1358 14–17 14–17 17–18 17–18
D13S317 12 12 14 14
Penta E 6–13 6–13 11–14 11–14
D16S539 10–13 10–13 12 12
D18S51 12–15 12–15 12–15 12–15
CSF1PO 12 12 12–14 12–14
Penta D 10–12 10–12 8–14 8–14
TH01 8 8 6 6
VWA 15–16 15–16 15–19 15–19
D21S11 29–31 29–31 29–33.2 29–33.2
D7S820 10–11 10–11 10–11 10–11
D5S818 11–13 11–13 11–13 11–13
TPOX 11–12 11–12 8 8
D8S1179 14 14 8 8
FGA 21–25 21–25 22–23 22–23
As shown in Figure 1, both primary cell cultures were positive for cone-rod homebox transcription
factor (CRX) by RT-qPCR and presented similar expression levels with respect to the commercial cell
line Y79.
Both small and large patient-derived tumorspheres, as well as Y79 cells, were positive stained
for arrestin 3 and synaptophysin, confirming the retinal and neuroectodermic tumor cell origin
(Figure 2A,B). Notwithstanding the size of the 3D model, all of them were histologically composed of
viable and proliferative tumor cells, as shown in Figure 2C,D, respectively.
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Taking into account the morphology, HPG-RBT-12L and HPG-RBT-26 cell cultures grew as freely
floating tridimensional structures in serum-free medium, matching the classification of seeding for
“spheres”. These 3D structures formed spontaneously in the culture media resulting in different sizes.
A representative image of small and large tumorspheres from both patients is depicted in Figure 3
showing the morphological features. Small tumorspheres from patient 1 and 2 (Figure 3A,B) showed
a median (range) diameter of 91 µm (53–109) and 53 µm (41–79), respectively. In the case of large
tumorspheres (Figure 3C,D), median diameters (range) were 353 µm (341–381) and 356 µm (334–385)
for patients 1 and 2, respectively.
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Figure 1. Expression of cone-rod homebox transcription factor in patient-derived cells.Expression of
the cone-rod homebox transcription factor (CRX) was determined by RT-qPCR and transcript levels
were quantified relative to the housekeeping gene and then normalized by the level of mRNA CRX
detected in Y79 cells. Data is shown as mean (SEM).
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Figure 2. Characterization of the tridimensional retinoblastoma cell structures. Representative small 
and large 3D tumor cell cultures resembling both spheres (HPG-RBT-12L) and dusts (Y79) show: (A) 
Cone photoreceptor-specific staining (ARR3). (B) synaptophysin stain confirming neuronal 
characteristics of the cells. (C) strong nuclear basophilic staining demonstrating they are composed of 
viable tumor cells; and (D) Ki-67 expression showing positive brown-staining all through the 3D 
structure. Scale bar, 100 μm. Images taken at 20× magnification. Abbreviations: ARR3, arrestin3; H&E, 
hematoxylin and eosin. 
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Figure 2. Characterization of the tridimensional retinoblastoma cell structures. Representative small
and large 3D tumor cell cultures resembling both spheres (HPG-RBT-12L) and dusts (Y79) show:
(A) Cone photoreceptor-specific staining (ARR3). (B) synaptophysin stain confirming neuronal
characteristics of the cells. (C) strong nuclear basophilic staining demonstrating they are composed of
viable tumo ells; and (D) Ki-67 expression showing positive brown-staining all through the 3D
structure. Scale bar, 100 µm. Images taken at 20× magnification. Abbreviations: ARR3, arrestin3; H&E,
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Figure 3. Representative confocal microscope images of in vitro tumorspheres derived from intraocular
retinoblastoma tumors. Small (A,B) and large (C,D) spherical aggregates of primary tumor cells
(HPG-RBT-12L and HPG-RBT-26 cells) obtained by culturing samples from intraocular tumors of
patients. Images taken at 20×magnification. Scale bar, 100 µm.
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2.2. Topotecan Penetration and Live-Cell Imaging
Confocal microscopy images were collected from 3D tumor models exposed to topotecan.
Supplementary Video 1 shows sequentially acquired and recorded images from a representative
experiment in a large HPG-RBT-12L tumorsphere before and 5 min after topotecan administration.
The penetration of the green color corresponds to topotecan fluorescence from the bathing solution into
the outer layers of the tumorsphere and thereafter into the core as a function of time. Different
rates of topotecan penetration were observed in tridimensional structures formed by Y79 cells
(fast penetration) and in patient-derived tumorspheres (slow penetration) (Figure 4). A uniform
green signal corresponding to topotecan fluorescence was observed even in large clusters, as topotecan
penetrated into the Y79 aggregates in less than 0.5 min due to the lack of strong cell-cell interactions,
as shown in Figure 4A. Y79 cells grow as loose clusters in suspension, resembling dust vitreous
seeds. This result was in contrast to the delayed penetration in patient-derived spheres. As shown
in Figure 4B, after 0.5 min of topotecan exposure, the spheres are black due to the lack of topotecan
penetration into the 3D structure. In large spheres, topotecan penetration into the tumorsphere was
evidenced by the progressive acquisition of green fluorescence from the outer to the core of the sphere
over 5 min of drug exposure (Supplementary Video 1).
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Figure 4. Topotecan penetration and activity in retinoblastoma 3D structures. (A) Topotecan
fluorescence as green color after 0.5 min of incubation in Y79 cells (dust model) and (B) in small
and large HPG-RBT-12L cells (sphere model). Note the absence of staining within small and large
spheres after incubation with topotecan for 0.5 min. (C) Cytotoxic activity of topotecan (1 µg/mL)
shown as accumulation of ethidium bromide in a tumorsphere treated for 10 min; dead nucleated
cells are stained red. (D) Control tumorsphere (untreated control) stained green with acridine orange.
Scale bar, 100 µm.
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The time for maximum topotecan accumulation into tumorspheres (tmax) was defined as the
time to achieve maximum fluorescence in the core of the sphere. A decrease in tumorsphere size
correlated with a shorter time for topotecan accumulation from the bathing solution into the core of
the tumorsphere for both cell models (p < 0.05; Table 2). However, no significant differences in tmax
were found between cell models for a similar size range (p > 0.05).
Table 2. Time to achieve maximum fluorescence in the core of small and large retinoblastoma spheres
from models HPG-RBT-12L and HPG-RBT-26.
tmax (min) HPG-RBT-12L tmax (min) HPG-RBT-26 P Value (t Test)
Small spheres 1.50 (0.29) 1.62 (0.12) 0.677
Large spheres 2.75 (0.14) 2.67 (0.17) 0.721
p-value (t test) 0.008 0.004
Abbreviations: tmax, time to achieve maximum fluorescence in the core of the sphere. Data is showed as mean (SEM) of
three independent experiments for each cell model.
2.3. Topotecan Cytotoxicity
In order to characterize the sensitivity of the cell lines to the chemotherapeutic agent,
we determined the IC50 of topotecan for the three cell cultures. Mean (range) topotecan IC50 in
Y79, HPG-RBT-12L, and HPG-RBT-26 cells was 28.6 nM (26.1–30.5), 12.3 nM (6.8–13.7), and 6.3 nM
(5.4–8.6), respectively. Topotecan IC50 in Y79 was similar to the value previously reported and
significantly higher than the values attained in HPG-RBT-12L and HPG-RBT-26 (p < 0.05). However,
no significant difference could be detected in topotecan IC50 between primary cell cultures (p > 0.05,
Figure S1).
Because topotecan needs at least 10 min to exert its cytotoxic activity in commercial cell
cultures [20], we assessed the cytotoxic effect of topotecan penetration into the spheres by ethidium
bromide staining after at least 10 min of topotecan exposure. As we used a concentration of topotecan
that was clinically relevant and higher than the IC50 determined in the cell cultures, it was expected
that topotecan would exert a cytotoxic effect in the tridimensional cell clusters. Complete cell damage
was observed by ethidium bromide red staining as shown in Figure 4C, compared to a control
(topotecan-free) tumorsphere stained as green with acridine orange (Figure 4D), supporting the
hypothesis that once inside the cells that composed the spheres, topotecan exerted cytotoxic activity.
3. Discussion
In this study, we established patient-derived retinoblastoma tridimensional culture resembling
the architecture of spheres, a class of vitreous seeds, and for the first time used live tumorsphere
imaging to gain insight into the penetration process of a chemotherapeutic agent in such tumor models.
After a thorough characterization of the cell lines, we took advantage of the fluorescence of topotecan
in conditions compatible with live-cell monitoring to visualize and quantify its penetration into the
core of tumorspheres derived from two patients with intraocular retinoblastoma and in cell clusters of
Y79 resembling spheres and vitreous dust seeds, respectively [7,8,11]. The quantification of topotecan
at different times based on the fluorescence intensity showed that drug penetration into the core of
the cell aggregates was immediate in dust, and faster in small than in large spheres. This result is
consistent with pathological observations stating that larger seeds consist of a greater number of cells
arranged in multilayers around a central core. Therefore, spheres are not mere aggregates of cells but
3D structures that may hamper drug accessibility.
The property of topotecan fluorescence has been used to quantify the drug in several biological
matrices for pharmacokinetic studies [12,14]. In addition, different researchers have exploited this
property to study the release rates of topotecan from liposomes and nanoparticles as part of the
development of new formulations, or to assess temporal variations in the disposition of topotecan in
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living cells or even whole animals using non-invasive fluorescence microscopy [21–24]. As a novel
application, we previously reported the use of fluorescent visualization of topotecan to evaluate the
safety of the injection technique and adequate drug delivery in retinoblastoma patients using a portable
Wood’s lamp [13].
Ours is the first study on the imaging of topotecan distribution in living retinoblastoma cells
spontaneously clustered in a 3D structure, as occurs in vivo. Previous studies on topotecan penetration
in tumorspheres were performed in other tumor cell lines forced to aggregate into a sphere by
gravity using the hanging drop technique [24,25]. In brief, the hanging drop technique consists of
plating droplets of cells in culture media on a lid, inverting the lid over a dish, and place it in an
incubator to allow for the 3D cell structure to form. Other researchers have worked with bioengineered
spheres consisting of commercial Y79 cells and gelatin microparticles as a scaffold to obtain the 3D
structure [26]. Specifically in that study, Y79 cells showed genomic alterations, including changes in
the expression of the collagen family when using microparticles as the matrix on which they were
grown. Thus, it may be expected that an altered drug penetration into the Y79-microparticle induced
by the culture conditions may not resemble the in vivo behavior of tumor seeds. In contrast, our
patient-derived tumor cells spontaneously grow as tumorspheres without the need for external forces,
or polymer support resembling floating vitreous seeds, as occurs in patients.
After upfront enucleation of two patients affected with retinoblastoma, we established two
patient-derived cell models. Then, we first confirmed the origin of the cell lines by different genomic
analysis and the identification of the expression of markers of retinal and neuronal tumor origin to
sustain the basis of all further developments. Importantly, cell-growth conditions avoiding the use of
serum for culturing the cells from the biopsy have been shown to dramatically improve tumor cell
selection and to avoid differentiation of the cell culture to a different phenotype than the parental
tumors [18,19]. Moreover, it is important to mention that cell-growth conditions and the cell line
passage number may result in different pharmacological sensitivity of the cell cultures as previously
reported for retinoblastoma and other tumors [27,28]. As shown in the present study, commercial
retinoblastoma cells spontaneously grow in loose aggregates of cells that allow almost instantaneous
drug penetration, likely resembling the dust vitreous seeds. Therefore, caution should be exercised if
using commercial cell lines but also different cell growth conditions to establish primary cell cultures of
retinoblastoma to use them as a basis of pharmacological screening and translation into the clinics.
The structural properties of the patient-derived tumorspheres were similar to vitreous seeds
classified as “spheres”, based on morphological and histopathological observations [7,8,11]. Patient
sphere sizes were reported to be in the range of 15 to 300 µm or even larger. In line with this observation,
our tumorspheres obtained from in vitro culture are also within that range (Figure 3). In addition, small
patient spheres displayed a homogeneous positive staining for Ki-67 as a marker of cell proliferation
widely used in tumor tissue biopsies. We also showed that large tumorspheres are composed of
multilayers of cells and that all cells located in the core or the surroundings were proliferative with
almost identical expression levels of Ki-67. Thus, our model was able to recapitulate the morphology
and phenotype of dusts and spheres of human vitreous seeds.
Importantly, the 3D multilayer cell structures may hinder drug penetration, and thus, diffusion
studies of active drugs in each in vitro model, and eventually the evaluation of drug sensitivity in
3D models should be performed [29,30]. We demonstrated, by means of confocal microscopy of
topotecan-treated spheres, that the drug penetrated upon the core of the tridimensional structures
in all cases. Also, we observed different rates of drug penetration, depending on the tridimensional
structure, resembling dusts or spheres, and the size of the in vitro spheres. Topotecan penetration
was almost immediate in clusters of Y79 cells as they gathered in a loose packing 3D structure. Thus,
although we observed a lower sensitivity to topotecan (higher topotecan IC50) of Y79 compared with
patient-derived tumor cells, the drug exerts its cytotoxic activity immediately after exposure of the
loose aggregates of Y79 cells. On the contrary, as a result of the multicellular architecture of the 3D
structures that allow cell-cell interactions, patient-derived spheres presented longer times of drug
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penetration into the core and also differences between sphere sizes. Nonetheless, topotecan penetrated
through all the evaluated 3D models and exerted a cytotoxic effect. These results obtained in vitro
show a strong cytotoxic activity of topotecan in Y79, and primary cell cultures may differ from the
clinical observation in retinoblastoma patients. Topotecan is usually administered with carboplatin or
melphalan based on the favorable ocular disposition, the synergistic cytotoxicity, and because of the
lack of documented clinical efficacy if administered as a single-agent [31].
Finally, and based on previous reports on the classification of vitreous seeds and the present results,
we may speculate that the longer it takes for topotecan to reach the inner layers of the tumorspheres,
the higher the number of doses of chemotherapy required for tumor control, as topotecan penetration
may be used as a surrogate for cytotoxicity. This assumption is based on the cytotoxic effect of
topotecan revealed by ethidium bromide after its penetration into the spheres. Nonetheless, the
relation between the number of doses and the actual dose of topotecan with the response in dusts,
spheres, and clouds should be assessed in clinics.
There are some limitations of the present 3D cell culture model that could be acknowledged.
Heterogeneity of patient samples may limit the generalization of drug response and penetration
rates through spheres that could be addressed if a larger number of samples are obtained to estimate
interindividual variability in drug response. However, the lack of fresh primary tumors, specifically
from patients enucleated upfront, and the difficulties in establishing primary tumor cell cultures
limit the availability of a wide range of 3D models for retinoblastoma. In addition, technical
challenges of the 3D cell culture technique relates to the ability of generating the same morphology
and size of the aggregates and to the mobility of free-floating spheroids in suspension, posing a
challenge to temporal imaging of the same spheroid. Also, it should be taken into account that the
present study was performed with topotecan and that other drugs used for retinoblastoma treatment,
including melphalan, may show different penetration rates into the 3D structures depending on the
physicochemical properties among other factors.
Altogether, we developed an in vitro tumor model that resembles retinoblastoma vitreous seeds
based on a close phenotype-genotype correlation. Under the cell culture conditions, these cells grow as
tumorspheres with the ability to interact in a 3D structure. Tumorspheres provide a valuable model to
study in vitro drug penetration as a surrogate for drug exposure in vitreous seeds that may be useful
to optimize drug therapy, and ultimately, to improve the efficacy of retinoblastoma treatment.
4. Materials and Methods
4.1. Ethics Statement
Patient retinoblastoma samples were obtained after protocol and informed consent approval
by Hospital de Pediatria JP Garrahan Institutional Review Board (protocol number 904, date of
approval: 26 February 2016). Written informed consent was obtained from parents or guardians before
sample collection.
4.2. Retinoblastoma Cell Line
The commercial cell line Y79 was obtained from the American Type Culture Collection (HTB-18,
Manassas, VA, USA). Cells were cultured at 37 ◦C with 5% CO2 in RPMI-1640 medium (Paisley,
Scotland, UK) with 20% fetal bovine serum (FBS, Internegocios, Cordoba, Argentina), as previously
reported elsewhere [19,27].
4.3. Establishment of Patient-Derived Cell Cultures
An ophthalmologist collected fresh primary tumor samples from patients with intraocular
retinoblastoma who underwent upfront enucleation as primary treatment. Tumor samples were
mechanically disaggregated and after centrifugation, and cells were cultured in serum-free neural
stem-cell medium as previously described for other pediatric stem cells culture conditions [19,27].
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Briefly, cells were grown in serum-free neurobasal medium (Thermo Fisher Scientific, Grand Island,
NY, USA) containing DMEM/F12 (Thermo Fisher Scientific), supplemented with B-27 (Thermo
Fisher Scientific), heparin (Sigma-Aldrich), EGF and FGF (epidermal and fibroblast growth factors,
respectively, Thermo Fisher Scientific), and PDGF (Platelet derived growth factor, PeproTech, Rocky
Hill, NJ, USA). Cultures were maintained at 37 ◦C in an incubator with a humidified atmosphere of 5%
CO2 and 95% air in T25 flasks at a density of approximately 106 cells/mL before starting the experiment.
4.4. Cell Authentication and Retinal Lineage Markers
Genomic DNA was isolated from cell lines, blood, and tumor samples using PureLink
Genomic DNA mini kit (Invitrogen, Carlsband, CA, USA) following the manufacturer’s instructions.
After checking the quality and quantity of the DNA by Nanodrop 2000 (Thermo Scientific, Waltham,
MA, USA), short tandem repeat (STR) profiling was performed in tumor samples and cell lines for
authenticating the origin of the cell lines by means of the analysis of 15 autosomal STR loci and
amelogenin. RB1 mutations were assessed by direct sequencing of the 27 exons and the promoter
region of the RB1 gene, and mutations were described with reference to GenBank accession #
L11910 [32]. Multiplex Ligation-dependent Probe Amplification assay (MLPA, MRC, Amsterdam,
The Netherlands) was performed according to the manufacturer´s protocol to screen for deletions or
duplications in the RB1 gene.
The expression of the photoreceptor lineage marker cone-rod homeobox transcription factor
(CRX) was analyzed to confirm the retinal tumor origin. Real-time quantitative PCR (RT-qPCR)
was used to evaluate the expression of CRX mRNA in the patient-derived cell cultures using
TaqMan technology in a 7500 Sequence Detection System (Applied Biosystems, Foster city, CA,
USA) [33]. Briefly, total RNAs was isolated from tumor cells using PureLink RNA Mini Kit
(Thermo Fisher Scientific) following the manufacturer´s instructions. After RNA quantitation using
NanoDrop spectrophotometer, RNA was reverse-transcribed into cDNA using random primers and
the SuperScript III kit (Invitrogen). The sequences of primers and probes used for RT-qPCR to analyze
CRX mRNA expression were as follows: Forward: 5′-AGGTGGCTCTGAAGATCAATCTG-3′, Reverse:
5′-TTAGCCCTCCGGTTCTTGAA-3′, and probe 5′-FAM-CTGAGTCCAGGGTTC-3′-MGB. Relative
expression of CRX mRNA was determined in cell cultures using the 2−∆∆Ct method, where Ct is the
threshold cycle of the target product and that of the housekeeping gene. Then, primary cell culture
data was normalized against CRX mRNA expression levels obtained in Y79.
Additionally, immunohistochemistry was performed in paraffin embedded cells for
synaptophysin (NCL-L-SYNAP-299, Leica BioSystems, Newcastle, UK) and arrestin 3 (ARR3,
11100-2-AP, Proteintech group, Chicago, IL, USA) expression to confirm the neuronal and cone-specific
origin of the cells, and hematoxylin-eosin staining for morphological assessment [19]. We also
evaluated the immunohistochemical staining for Ki-67 as a marker of proliferating but not quiescent
(G0 phase) cells using Ki-67 antibody (Ki-67 anti-human clone, Dako, Denmark), and the percentage of
Ki-67 positive cells was compared between tumorspheres of different sizes and origins. The percentage
of Ki-67 positive cells was calculated using ImageJ software (NIH, Bethesda, MD, USA) [34].
4.5. Live-Cell Confocal Microscopy
To quantify the penetration of topotecan into retinoblastoma patient-derived spheres, two sizes of
tumorspheres were considered based on visual inspection with the microscope. ”Small” (< 110 µm)
and “large” (110–400 µm) tumorspheres were classified according to the diameter calculated from an
optical slice corresponding to approximately the middle of each sphere.
First, cell culture viability was evaluated by means of trypan blue exclusion assay. Then,
ten microliters of each cell suspension of approximately 106 cells/mL were seeded on a slide covered
by a clean 15 mm round coverslip, and an appropriate field with tumorspheres was located. Untreated
tumorspheres were evaluated for natural fluorescence in a separate experiment. As shown in
Supplemental Figure S2A, there was no acquisition of signal before topotecan exposure, while after
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6 min of drug addition to the medium (Figure S2B), the sphere acquired a complete green fluorescence
due to topotecan penetration. Then, 1 µL of a 10 µg/mL solution of topotecan (final concentration
1 µg/mL) was added. This concentration was selected based on the dose of topotecan commonly
used for intravitreal injection (30 µg) and the volume of distribution in human vitreous humor (4 mL),
resulting in an in vivo concentration similar to that used for in vitro evaluation [35,36]. Immediately
after, and thereafter every 30 s, fluorescent images were obtained using an Olympus Fluoview FV1000
confocal laser scanning microscope (Olympus, Tokyio, Japan) with imaging software (Olympus
Fluoview FV10-ASW v1.7c, Melville, NY, USA), and equipped with a UPlanSApo 20X/0.75 NA
objective. Excitation was provided by a 458 nm line of a multiline argon laser at a 25% transmittance,
and fluorescent images were collected with a 505–605 nm emission filter. Images were collected
with a format of 1024 × 1024 pixels. Topotecan penetration into the tumorsphere was determined
in terms of fluorescence intensity and images were processed using ImageJ software. At least
three tumorspheres from each size were assessed for each patient-derived model. Autofluorescence
contribution (natural fluorescence contribution of untreated tumorspheres) was evaluated in a different
experiment. All optical images collected from each tumorsphere were sequentially acquired and
recorded on video using ImageJ software.
Images were processed to quantify the penetration of topotecan into the sphere, as follows. First,
anisotropic diffusion filtering was applied to smooth noise and defined region boundaries of each
tumorsphere [37]. Then, the Otsu’s thresholding segmentation method was used for segmenting
the spheres from the background and also inside each tumorsphere to calculate the percentage of
change of black and white pixels as a function of time as a surrogate of topotecan penetration [38,39].
The time to achieve maximum fluorescence in the core of the tumorsphere as a surrogate of complete
penetration of topotecan was defined as the time needed for obtaining at least 90% of white pixels.
4.6. Topotecan Cytotoxicity and Cell Viability Assay
Topotecan cytotoxicity was evaluated in each cell culture to determine the concentration of
drug that causes a 50% decrease in cell proliferation or IC50, as previously reported [20,27]. Briefly,
cells were counted, seeded in 96-well plates, cultured for 24 hours, and thereafter exposed to
different concentrations of topotecan (0.001–1.000 nM). After incubation for 72 h, cell proliferation
was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric
assay. The IC50 was calculated using GraphPad Prism v.6 (GraphPad, San Diego, CA, USA).
At the end of the study, tumorspheres were stained using ethidium bromide (100 µg/mL,
Sigma Aldrich) and acridine orange (100 µg/mL) double-staining for the visualization of nucleic
acids of membrane-damaged cells (necrotic or cells in late apoptosis induced by topotecan, observed
as stained red) and live cells (stained green), respectively, and observed under fluorescence microscope.
As both reagents were added simultaneously, non-specific signals to acridine orange of ethidium
bromide could be assessed in topotecan-treated and untreated 3D structures, respectively.
4.7. Statistical Analysis
Comparison of the time needed for topotecan to fully penetrate into the core of the two sizes of
tumorspheres derived from patients was performed by means of a t test with a significance p-value
of 0.05.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/20/5/
1077/s1.
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